Kazia Therapeutics Limited (KZIA) Dividend History
Income profile from 1999 to 2025 with payout safety and yield-on-cost trend
KZIA Dividend Income Check
Safety
Payout ratio data not available yet.
Consistency
0 straight years of dividend increases.
Income Trend
Yield on cost trend needs more history.
KZIA Dividend Scorecard
Yield & Income
Payout Safety
Growth
Total Returns
Uses precomputed total return metrics from screening data (not lot-by-lot dividend reinvestment transactions). Different time windows can produce different outcomes depending on market regime and entry point.
KZIA Dividend History
No dividend payment history available
Get KZIA's next ex-dividend date and payout in your inbox
Monthly dividend calendar — upcoming ex-dates for stocks you follow.
Dividend Analysis
Payout Safety
Kazia Therapeutics Limited has limited earnings payout data (Unknown).
Piotroski F-Score: 2/9 — weak financial health.
Growth Track Record
KZIA does not have a current streak of consecutive dividend increases.
Total Shareholder Returns
Beyond cash dividends, KZIA returns capital through share repurchases. The combined picture: 0.0% total shareholder yield.
Income Trend & Total Return
The 5-year total return is -97.3%.
DRIP Growth
A $10,000 investment made 10 years ago with dividends reinvested would have grown to approximately $350 today.
KZIA Annual Dividend History (1999–2025)
27 years of dividend data
| Year | DPS | YoY | Pmts | EPS | Payout | Coverage | YOC |
|---|---|---|---|---|---|---|---|
| 2025 | $0.00 | — | 0 | $-18.90 | — | — | — |
| 2024 | $0.00 | — | 0 | $-55.00 | — | — | — |
| 2023 | $0.00 | — | 0 | $-55.00 | — | — | — |
| 2022 | $0.00 | — | 0 | $-95.00 | — | — | — |
| 2021 | $0.00 | — | 0 | $-35.80 | — | — | — |
| 2020 | $0.00 | — | 0 | $-80.00 | — | — | — |
| 2019 | $0.00 | — | 0 | $-85.60 | — | — | — |
| 2018 | $0.00 | — | 0 | $-59.80 | — | — | — |
| 2017 | $0.00 | — | 0 | $-109.30 | — | — | — |
| 2016 | $0.00 | — | 0 | $-135.20 | — | — | — |
What if you invested $1,000 in KZIA back in 1999?
Total return with dividends reinvested · 27+ years of data
Calculate ReturnsHow much would $100/month in KZIA be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs KZIA Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationKZIA vs LLY — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.
Compare NowKZIA — Frequently Asked Questions
Quick answers to the most common questions about buying KZIA stock.
How much dividend does KZIA pay per share?
Kazia Therapeutics Limited (KZIA) pays a trailing 12-month dividend of N/A per share, with a current dividend yield of N/A. Payments are made quarterly.
When is KZIA's next ex-dividend date?
KZIA's most recent ex-dividend date is N/A. You must own shares before the ex-dividend date to receive the next payment. KZIA typically pays dividends quarterly.
Is KZIA's dividend safe?
KZIA's dividend safety is rated "Unknown" based on an earnings payout ratio of N/A and FCF payout ratio of N/A. The dividend history does not yet show a prolonged growth streak.
How many years has KZIA increased its dividend?
KZIA has not maintained a consecutive growth streak recently. The 5-year dividend CAGR is N/A.
How often does KZIA pay dividends?
Kazia Therapeutics Limited pays dividends quarterly. The trailing 12-month total is N/A per share. Dividend data on this page covers 26+ years from 1999 to 2025.
How much would $10,000 invested in KZIA grow with dividend reinvestment?
With dividends reinvested (DRIP), $10,000 invested in KZIA five years ago would be worth approximately $271 today. This includes both price appreciation and compounded dividend reinvestment. Use the DRIP calculator above for other time periods.
What is KZIA's yield on cost for long-term holders?
KZIA's yield on cost — the current dividend divided by the original purchase price — is N/A for a 5-year holding period. This means long-term holders earn a higher effective yield than today's N/A market yield, thanks to the lower original cost basis.